Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 150Squamous Cell Carcinoma of Head and Neck 76Head and Neck Neoplasms 75Stomach Neoplasms 52Lung Neoplasms 52Esophageal Neoplasms 34Neoplasms 33Uterine Cervical Neoplasms 32Urinary Bladder Neoplasms 32Carcinoma, Squamous Cell 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Neoplasm Metastasis 26Small Cell Lung Carcinoma 23Breast Neoplasms 23Cholangiocarcinoma 21Carcinoma 19Ovarian Neoplasms 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Pancreatic Neoplasms 13Oropharyngeal Neoplasms 13Mesothelioma, Malignant 13Adenocarcinoma 13Biliary Tract Neoplasms 12Mesothelioma 11Gallbladder Neoplasms 11Esophageal Squamous Cell Carcinoma 10Carcinoma, Transitional Cell 10Tongue Neoplasms 9Laryngeal Neoplasms 9

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Non Small Cell Lung Carcinoma NSCLC × Cisplatin × Clear all
NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡